5021-33-0

Usage

Uses

Used in Organic Synthesis:
(1-methylpyrrolidin-3-yl)methanol is used as a reagent in organic synthesis for its ability to facilitate various chemical reactions, contributing to the formation of complex organic compounds.
Used in Pharmaceutical Development:
In the pharmaceutical industry, (1-methylpyrrolidin-3-yl)methanol is used as a building block for the synthesis of various pharmaceuticals and organic compounds, playing a crucial role in the development of new medications.
Used in Medical Treatments:
(1-methylpyrrolidin-3-yl)methanol is studied for its potential use in the treatment of medical conditions such as depression and anxiety disorders, indicating its therapeutic value in mental health care.
Used as an Intermediate in Chemical and Pharmaceutical Manufacturing:
(1-methylpyrrolidin-3-yl)methanol also serves as an intermediate in the manufacturing process of various chemicals and pharmaceutical products, highlighting its importance in the production of a wide range of consumer and industrial goods.

InChI:InChI=1/C6H13NO/c1-7-3-2-6(4-7)5-8/h6,8H,2-5H2,1H3

Upstream product

• 118870-35-2 1-(1-methyl-pyrrolidin-3-yl)-ethane-1,2-diol 
• 25712-60-1 1-methyl-pyrrolidine-3-carboxylic acid 
• 112970-91-9 hydroxy-(1-methyl-2-oxo-pyrrolidin-3-yl)-acetic acid ethyl ester 
• 60044-10-2 ethyl (1-methyl-2-oxopyrrolidin-3-yl)(oxo)acetate 
• 872-50-4 1-methyl-pyrrolidin-2-one 
• 1184-78-7 trimethylamine-N-oxide 
• 107-18-6 allyl alcohol 

Downstream Products

• 1279125-95-9 4-[(4-chlorophenyl)methyl]-2-(1-methyl-3-pirrolidinylmethyl)-1(2H)-phthalazinone 
• 1417646-26-4 C₂₄H₂₆N₂O₅ 
• 1417646-47-9 C₂₈H₃₂N₂O₅ 
• 1417646-35-5 C₃₀H₃₄N₂O₆ 

Relevant academic research and scientific papers

QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE

The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).

Deprotonation de N-oxydes d'amines aliphatiques: schema reactionnel general et nouvelle synthese de pyrrolidines

Amine oxides, 1, 5, 10, 15, 21, 23, when treated by lithium diisopropylamide undergo deprotonation.Monodeprotonation gives rise either to secondary amines and benzaldehyde resulting from the hydrolysis of an intermediate immonium (I) or to hydroxylamines via a Stevens-like rearrangement observed for the first time on an amine oxide.Double deprotonation gives an immonium ylid (Y) which, depending upon the structure of the initial tertiary amine yields either "head to head" piperazines (biradical-like behavior of (DD)) or aziridines.The immonium ylid (Y5) derived from trimethylamine oxide, whose formation and reactivity are reported for the first time, has remarkable property of undergoing cycloaddition reactions with unactivated olefins, leading to a new and efficient synthesis of various pyrrolidines.